Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire - Fri Dec 6, 7:00AM CST

PCRX : 18.98 (-3.01%)
Pacira BioSciences Announces Issuance of New EXPAREL Patent, Expanding Intellectual Property Protection to 2044 Quiver Quantitative, Inc. - Tue Dec 3, 4:48PM CST

Pacira BioSciences announced a new U.S. patent for EXPAREL, extending its intellectual property protection into 2044.Quiver AI SummaryPacira BioSciences, Inc. announced the issuance of U.S. Patent No....

PCRX : 18.98 (-3.01%)
Pacira Awarded New U.S. Patent Covering EXPAREL Composition GlobeNewswire - Tue Dec 3, 6:30AM CST

PCRX : 18.98 (-3.01%)
Pacira BioSciences Reports Sustained Pain Relief in Osteoarthritis with Gene Therapy Candidate PCRX-201 in Upcoming ACR Presentation Quiver Quantitative, Inc. - Thu Nov 14, 8:00PM CST

Pacira BioSciences reports positive data on gene therapy PCRX-201 for knee osteoarthritis, showing sustained pain relief for 104 weeks.Quiver AI SummaryPacira BioSciences, Inc. recently revealed promising...

PCRX : 18.98 (-3.01%)
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee GlobeNewswire - Thu Nov 14, 9:05AM CST

PCRX : 18.98 (-3.01%)
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences GlobeNewswire - Tue Nov 12, 7:00AM CST

PCRX : 18.98 (-3.01%)
Pacira: Q3 Earnings Snapshot AP - Wed Nov 6, 3:10PM CST

Pacira: Q3 Earnings Snapshot

PCRX : 18.98 (-3.01%)
Pacira BioSciences Reports Third Quarter 2024 Financial Results GlobeNewswire - Wed Nov 6, 3:00PM CST

PCRX : 18.98 (-3.01%)
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings GlobeNewswire - Mon Nov 4, 7:00AM CST

PCRX : 18.98 (-3.01%)
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 GlobeNewswire - Wed Oct 30, 7:00AM CDT

PCRX : 18.98 (-3.01%)

Barchart Exclusives

Love Dividends? 2 Passive Income Stocks to Scoop Up Now. Barchart - 18 minutes ago
These consistent dividend-paying stocks could be a good addition to your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot